JP2020517631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517631A5 JP2020517631A5 JP2019556830A JP2019556830A JP2020517631A5 JP 2020517631 A5 JP2020517631 A5 JP 2020517631A5 JP 2019556830 A JP2019556830 A JP 2019556830A JP 2019556830 A JP2019556830 A JP 2019556830A JP 2020517631 A5 JP2020517631 A5 JP 2020517631A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oligonucleotide
- population
- item
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487420P | 2017-04-19 | 2017-04-19 | |
| US62/487,420 | 2017-04-19 | ||
| PCT/US2018/028263 WO2018195250A1 (en) | 2017-04-19 | 2018-04-19 | P-ethoxy nucleic acids for igf-1r inhibition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517631A JP2020517631A (ja) | 2020-06-18 |
| JP2020517631A5 true JP2020517631A5 (https=) | 2021-05-20 |
| JP7186721B2 JP7186721B2 (ja) | 2022-12-09 |
Family
ID=63856102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556830A Active JP7186721B2 (ja) | 2017-04-19 | 2018-04-19 | Ｉｇｆ－１ｒ阻害のためのｐ－エトキシ核酸 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210115451A1 (https=) |
| EP (1) | EP3612162A4 (https=) |
| JP (1) | JP7186721B2 (https=) |
| KR (1) | KR102657218B1 (https=) |
| CN (1) | CN110650727A (https=) |
| AU (1) | AU2018255353B2 (https=) |
| CA (1) | CA3057974A1 (https=) |
| WO (1) | WO2018195250A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3362563A1 (en) | 2015-10-14 | 2018-08-22 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for liposomal formulation |
| JP7132911B2 (ja) | 2016-09-16 | 2022-09-07 | バイオ－パス ホールディングス， インコーポレイテッド | リポソームアンチセンスオリゴヌクレオチドとの併用療法 |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| EP3612160A4 (en) | 2017-04-19 | 2021-01-20 | Bio-Path Holdings, Inc. | P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION |
| CN114369130B (zh) * | 2021-12-28 | 2023-10-03 | 杭州天龙药业有限公司 | 修饰的硫代寡核苷酸及其应用 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US7704962B1 (en) * | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| WO2000009145A1 (en) * | 1998-08-13 | 2000-02-24 | Thomas Jefferson University | Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor |
| US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
| EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| CA2982205A1 (en) * | 2015-04-10 | 2016-10-13 | David W. Andrews | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| EP3362563A1 (en) * | 2015-10-14 | 2018-08-22 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for liposomal formulation |
-
2018
- 2018-04-19 WO PCT/US2018/028263 patent/WO2018195250A1/en not_active Ceased
- 2018-04-19 KR KR1020197033981A patent/KR102657218B1/ko active Active
- 2018-04-19 CA CA3057974A patent/CA3057974A1/en active Pending
- 2018-04-19 JP JP2019556830A patent/JP7186721B2/ja active Active
- 2018-04-19 AU AU2018255353A patent/AU2018255353B2/en active Active
- 2018-04-19 CN CN201880033242.7A patent/CN110650727A/zh active Pending
- 2018-04-19 US US16/606,433 patent/US20210115451A1/en not_active Abandoned
- 2018-04-19 EP EP18788505.8A patent/EP3612162A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517631A5 (https=) | ||
| US10982210B2 (en) | Compositions for delivery of cargo to cells | |
| JP5850915B2 (ja) | 肺送達のためのベクター、導入剤及び使用 | |
| US8440811B2 (en) | DNA nanostructures that promote cell-cell interaction and use thereof | |
| JP2021500064A5 (https=) | ||
| AU2017203714A1 (en) | Immunostimulatory oligonucleotides | |
| IL273980B2 (en) | Phosphorylated tau peptide preparations and uses thereof | |
| JP2021526860A5 (https=) | ||
| JP2020517645A5 (https=) | ||
| CN107548401A (zh) | 用于细胞内递送分子的肽和纳米颗粒 | |
| JP2014518612A5 (https=) | ||
| JP2015521626A5 (https=) | ||
| CN101874112A (zh) | 特别是作为免疫刺激剂/佐剂的式(Ⅰ):G1XmGn或式(Ⅱ):C1XmCn的核酸 | |
| WO2013030831A2 (en) | Pathogen and substance traps | |
| JP6893245B2 (ja) | 脂質ナノ粒子用膜材料組成物 | |
| TW201723178A (zh) | 具拮抗ｐｄｌ１功能的適體分子於癌症治療之應用 | |
| JP2018534361A5 (https=) | ||
| JP2021500016A5 (https=) | ||
| JPH11504926A (ja) | 核酸リガンド複合体 | |
| JP2022518479A5 (https=) | ||
| JP2020526530A5 (https=) | ||
| CN103071161A (zh) | 聚阳离子脂质体/磷酸钙纳米粒给药载体的制备方法 | |
| Tolstonog et al. | Interaction in vitro of type III intermediate filament proteins with higher order structures of single-stranded DNA, particularly with G-quadruplex DNA | |
| JP2020517646A5 (https=) | ||
| KR20170054429A (ko) | 치료용 나노입자 및 관련 조성물, 방법, 및 시스템 |